The mission of the Vanderbilt O'Brien Kidney Center (VOKC) is to advance research opportunities for kidney related research and promote effective interactions between basic scientists and clinical researchers in order to advance effective prevention and treatment of acute and chronic kidney disease and their complications. To accomplish its mission, the Vanderbilt O'Brien Kidney Center supports Biomedical Research Cores, Pilot and Feasibility Grants and a robust Educational Enrichment Program. There are three Biomedical Research Cores that provide services to investigators utilizing preclinical models of kidney injury: a Phenotyping and Pathophysiology Core, an Histology and Molecular Pathology Core and a Cell and Genome Engineering Core and a robust Clinical and Translation Core for investigators involved in translational and epidemiologic research. These Cores support kidney research that is conducted by 92 investigators at Vanderbilt. In addition, our goal in developing the VOKC is for it to serve as a national and international resource, and, as indicated in the description of the Biomedical Research Base, investigators at institutions in both the U.S. and abroad have utilized resources of the Biomedical Core; in addition, we have provided services to a number of pharmaceutical companies. During its previous funding period, the Center supported studies that have provided new insights into the pathogenesis and treatment of diabetic nephropathy, hypertension, acute kidney injury, glomerular and tubulointerstitial fibrosis and complications of chronic kidney disease.

Public Health Relevance

Mission of the Vanderbilt O'Brien Kidney Center The mission of the Vanderbilt O'Brien Kidney Center (VOKC) is to advance research opportunities for kidney-related research and promote effective interactions between basic scientists and clinical researchers in order to advance effective prevention and treatment of acute and chronic kidney disease and their complications. To accomplish its mission, the Vanderbilt O'Brien Center supports Biomedical Research Cores, Pilot and Feasibility Grants and a robust Educational Enrichment Program. These Cores support kidney research that is conducted by >90 investigators at Vanderbilt and will serve as a national and international resource.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
1P30DK114809-01
Application #
9385111
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Kimmel, Paul
Project Start
2017-09-08
Project End
2022-06-30
Budget Start
2017-09-08
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Chung, Sungjin; Overstreet, Jessica M; Li, Yan et al. (2018) TGF-? promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight 3:
Wang, Feng; Katagiri, Daisuke; Li, Ke et al. (2018) Assessment of renal fibrosis in murine diabetic nephropathy using quantitative magnetization transfer MRI. Magn Reson Med 80:2655-2669
Li, Yan; Chung, Sungjin; Li, Zhilian et al. (2018) Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight 3:
Wang, Feng; Takahashi, Keiko; Li, Hua et al. (2018) Assessment of unilateral ureter obstruction with multi-parametric MRI. Magn Reson Med 79:2216-2227
Zhang, Ming-Zhi; Wang, Suwan; Wang, Yinqiu et al. (2018) Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity. Hypertension 72:1172-1179
Zhu, Lin; Luu, Thao; Emfinger, Christopher H et al. (2018) CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes 67:2494-2506
Borza, Corina M; Pozzi, Ambra; Plosa, Erin J (2018) Discoidin Domain Receptor 2, a Potential Therapeutic Target in Lung Fibrosis. Am J Respir Cell Mol Biol 59:277-278
Lim, Beom Jin; Yang, Jae Won; Zou, Jun et al. (2017) Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. Kidney Int 92:1395-1403